References
- Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7:201–204.
- FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD); Bethesda (MD): Food and Drug Administration (US); 2016-. Predictive Biomarker. Co-published by National Institutes of Health (US). 2016 Dec 22 [cited 2022 Jul 28]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK402283/
- Jørgensen JT, Winther H, Askaa J, et al. A companion diagnostic with significant clinical impact in treatment of breast and gastric cancer. Front Oncol. 2021;11:676939.
- Food and Drug Administration. List of cleared or approved companion diagnostic devices (In vitro and imaging tools). [ updated 2022 Jun 30; cited 2022 Jul 29]. Available from: https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools
- Food and Drug Administration. Drugs@FDA: FDA-approved drugs. [ cited 2022 Jul 29]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- Food and Drug Administration. Guidance for industry and food and drug administration staff. In vitro companion diagnostic devices. 2014 Aug 6 [cited 2022 Jul 29]. Available from: https://www.fda.gov/media/81309/download
- Conn CW, Jin J. The value of companion diagnostics in oncology drug development. Expert Rev Mol Diagn. 2022;1–3. DOI:10.1080/14737159.2022.2100697
- Jørgensen JT. Missing companion diagnostic for US Food and Drug Administration-approved hematological and oncological drugs. JCO Precis Oncol. 2022;6:e2200100.
- Bahar MA, Setiawan D, Hak E, et al. Pharmacogenetics of drug–drug interaction and drug–drug–gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. Pharmacogenomics. 2017;1(8):701–739.
- Samwald M, Xu H, Blagec K, et al. Incidence of exposure of patients in the United States to multiple drugs for which pharmacogenomic guidelines are available. PLoS One. 2016 Oct 20;11(10):e0164972.
- Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol. 2019;12:407–442.
- Ramsey LB, Johnson SG, Caudle KE, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014;96:423–428.
- Barbarino JM, Whirl-Carrillo M, Altman RB, et al. PharmGKB: a worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018;10:e1417.
- Food and Drug Administration. Table of Pharmacogenetic Associations. [ update 2022 May 24; cited 2022 Aug 28]. Available from: https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations
- Cicali EJ, Elchynski AL, Cook KJ, et al. How to integrate CYP2D6 phenoconversion into clinical pharmacogenetics: a tutorial. Clin Pharmacol Ther. 2021;110:677–687.
- Westergaard N, Tarnow L, Vermehren C. Use of clopidogrel and proton pump inhibitors alone or in combinations in persons with diabetes in Denmark; Potential for CYP2C19 genotype-guided drug therapy. Metabolites. 2021;11:96.